Trends in resistance to antiretroviral drugs for HIV-1 may inform clinical support and drug development. We evaluated drug resistance mutation (DRM) trends for nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), and integrase strand transfer inhibitor (INSTI) in a large U.S. reference laboratory database. DRMs with a Stanford HIV Drug Resistance Database mutation score ≥10 from deidentified subtype B NRTI/NNRTI/PI specimens (2006–2017; >10,000/year) and INSTI specimens (2010–2017; >1,000/year) were evaluated. Sequences with NRTI, NNRTI, or PI single- or multiclass DRMs declined from 48.9% to 39.3%. High-level dual- and triple-class resistance declined from 43.3% (2006) to 17.1% (2017), while sequences with only single-class DRMs increased from 40.0% to 52.9%. The prevalence of DRMs associated with earlier treatment regimens declined, while prevalence of some DRMs associated with newer regimens increased. M184V/I decreased from 48.3% to 29.4%. K103N/S/T declined from 42.5% in 2012 to 36.4% in 2017. Rilpivirine and etravirine DRMs E138A/Q/R and E138K increased from 4.9% and 0.4% to 9.7% and 1.7%, respectively. Sequences with ≥1 darunavir DRM declined from 18.1% to 4.8% by 2017. INSTI DRM Q148H/K/R declined from 39.3% (2010) to 13.8% (2017). Prevalence of elvitegravir-associated DRMs T66A/I/K, E92Q, S147G, and the dolutegravir-associated DRM R263K increased. For a subset of patients with serial testing, 50% (2,646/5,290) of those who initially had no reportable DRM subsequently developed ≥1 DRM for NRTI/NNRTI/PI and 49.7% (159/320) for INSTI. These trends may inform the need for baseline genotypic resistance testing. The detection of treatment-emergent DRMs in serially tested patients confirms the value of genotypic testing following virologic failure.
Get full access to this article
View all access options for this article.
References
1.
MurphyEL, CollierAC, KalishLA, et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med, 2001; 135:17–26.
2.
PalellaFJ Jr., DelaneyKM, MoormanAC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998; 338:853–860.
3.
AnglemyerA, RutherfordGW, HorvathT, BaggaleyRC, EggerM, SiegfriedN: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev, 2013:CD009153.
4.
JeanK, GabillardD, MohR, et al.: Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Cote d'Ivoire. J Infect Dis, 2014; 209:431–440.
5.
SafrenSA, MayerKH, OuSS, et al.: Adherence to early antiretroviral therapy: Results from HPTN 052, a phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. J Acquir Immune Defic Syndr, 2015; 69:234–240.
6.
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2018, pp. 1–298. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
7.
ClutterDS, JordanMR, BertagnolioS, ShaferRW: HIV-1 drug resistance and resistance testing. Infect Genet Evol, 2016; 46:292–307.
8.
SaagMS, BensonCA, GandhiRT, et al.: Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA, 2018; 320:379–396.
9.
CoffinJM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science, 1995; 267:483–489.
10.
ManskyLM: HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updat, 2002; 5:219–223.
11.
WensingAM, CalvezV, GunthardHF, et al.: 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med, 2017; 24:132–133.
12.
Menendez-AriasL: Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res, 2013; 98:93–120.
BaxterJD, DunnD, WhiteE, et al.: Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med, 2015; 16Suppl 1:77–87.
15.
KassayeSG, GrossmanZ, BalamaneM, et al.: Transmitted HIV drug resistance is high and longstanding in metropolitan Washington, DC. Clin Infect Dis, 2016; 63:836–843.
16.
RheeSY, ClutterD, FesselWJ, et al.: Trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance in a large U.S. clinic population. Clin Infect Dis, 2019; 68:213–221.
17.
WensingAM, van de VijverDA, AngaranoG, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis, 2005; 192:958–966.
18.
WheelerWH, ZiebellRA, ZabinaH, et al.: Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses U.S.-2006. AIDS, 2010; 24:1203–1212.
19.
YanikEL, NapravnikS, HurtCB, et al.: Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr, 2012; 61:258–262.
20.
DrescherSM, von WylV, YangWL, et al.: Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis, 2014; 58:285–294.
21.
MargotNA, WongP, KulkarniR, et al.: Commonly transmitted HIV-1 drug resistance mutations in reverse-transcriptase and protease in antiretroviral treatment-naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide. J Infect Dis, 2017; 215:920–927.
22.
PanichsillapakitT, SmithDM, WertheimJO, RichmanDD, LittleSJ, MehtaSR: Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996–2013. J Acquir Immune Defic Syndr, 2016; 71:228–236.
23.
DunnDT, CoughlinK, CanePA: Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS, 2011; 6:251–257.
24.
GrantPM, ZolopaAR: The use of resistance testing in the management of HIV-1-infected patients. Curr Opin HIV AIDS, 2009; 4:474–480.
25.
De LucaA, DunnD, ZazziM, et al.: Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis, 2013; 207:1216–1220.
26.
PaquetAC, SolbergOD, NapolitanoLA, et al.: A decade of HIV-1 drug resistance in the United States: Trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012. Antivir Ther, 2014; 19:435–441.
27.
BuchaczK, BakerR, WardDJ, et al.: Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999–2008. AIDS Res Treat, 2012; 2012:230290.
28.
BennettDE, CamachoRJ, OteleaD, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 2009; 4:e4724.
29.
ParedesR, TzouPL, van ZylG, et al.: Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One, 2017; 12:e0181357.
30.
TangMW, LiuTF, ShaferRW: The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology, 2012; 55:98–101.
31.
DelaugerreC, FlandreP, MarcelinAG, et al.: National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. J Med Virol, 2008; 80:762–765.
32.
Sluis-CremerN, SheenCW, ZelinaS, TorresPS, ParikhUM, MellorsJW: Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother, 2007; 51:48–53.
33.
AntaL, LlibreJM, PovedaE, et al.: Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS, 2013; 27:81–85.
34.
KulkarniR, BabaogluK, LansdonEB, et al.: The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr, 2012; 59:47–54.
35.
RimskyL, VingerhoetsJ, Van EygenV, et al.: Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr, 2012; 59:39–46.
36.
TambuyzerL, NijsS, DaemsB, PicchioG, VingerhoetsJ: Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr, 2011; 58:18–22.
37.
de MeyerS, VangeneugdenT, van BaelenB, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses, 2008; 24:379–388.
38.
JohnsonVA, CalvezV, GunthardHF, et al.: Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med, 2013; 21:6–14.
39.
De MeyerS, DierynckI, LathouwersE, et al: Phenotypic and genotypic determinants of resistance to darunavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. [Abstract 31]. Antivir Ther, 2008; 13:A33.
40.
AbramME, HluhanichRM, GoodmanDD, et al.: Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother, 2013; 57:2654–2663.
41.
EronJJ, ClotetB, DurantJ, et al.: Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis, 2013; 207:740–748.
42.
FransenS, GuptaS, DanovichR, et al.: Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol, 2009; 83:11440–11446.
43.
KobayashiM, YoshinagaT, SekiT, et al.: In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother, 2011; 55:813–821.
44.
LlibreJM, PulidoF, GarciaF, Garcia DeltoroM, BlancoJL, DelgadoR: Genetic barrier to resistance for dolutegravir. AIDS Rev, 2015; 17:56–64.
45.
SekiT, Suyama-KagitaniA, Kawauchi-MikiS, et al.: Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother, 2015; 59:2596–2606.
46.
WainbergMA, HanYS: Will drug resistance against dolutegravir in initial therapy ever occur?. Front Pharmacol, 2015; 6:90.
47.
MespledeT, QuashiePK, OsmanN, et al.: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology, 2013; 10:22.
48.
QuashiePK, MespledeT, HanYS, et al.: Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol, 2012; 86:2696–2705.
49.
BrennerBG, ThomasR, BlancoJL, et al.: Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother, 2016; 71:1948–1953.
50.
QuashiePK, MespledeT, HanYS, et al.: Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother, 2013; 57:6223–6235.
51.
RheeSY, SankaranK, VargheseV, et al.: HIV-1 protease, reverse transcriptase, and integrase variation. J Virol, 2016; 90:6058–6070.
52.
SilicianoJD, SilicianoRF: Recent trends in HIV-1 drug resistance. Curr Opin Virol, 2013; 3:487–494.
53.
MillerMD, HaddadM, SuC, GibbsC, McCollDJ, GuyerB: Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003–2010. Antivir Ther, 2012; 17:993–999.
54.
HaddadM, NapolitanoLA, PaquetA, et al.: Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility [Abstract 10]. Antivir Ther, 2011; 16:A18.
55.
LlibreJM: First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients—Making a good thing better. AIDS Rev, 2009; 11:215–222.
56.
LathouwersE, WongEY, LuoD, SeyedkazemiS, De MeyerS, BrownK: HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials, 2017; 18:196–204.
57.
LathouwersE, GuptaS, HaddadM, PaquetA, de MeyerS, BaughB: Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012. AIDS Res Hum Retroviruses, 2015; 31:628–635.
58.
BrownK, StewartL, WhitcombJ, YangD, NettlesRE, LathouwersE: Prevalence of darunavir resistance in the United States from 2010 to 2017. AIDS Res Hum Retroviruses, 2018; 34:1036–1043.
59.
KoulliasY, SaxPE, FieldsNF, WalenskyRP, HyleEP: Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus?. Clin Infect Dis, 2017; 65:1274–1281.
60.
ScherrerAU, YangWL, KouyosRD, et al.: Successful prevention of transmission of integrase resistance in the Swiss HIV cohort study. J Infect Dis, 2016; 214:399–402.
61.
AldousAM, CastelAD, ParentiDM: Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014. BMC Res Notes, 2017; 10:474.
62.
SmithSJ, ZhaoXZ, BurkeTR Jr., HughesSH: Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology, 2018; 15:37.
63.
MespledeT, WainbergMA: Is resistance to dolutegravir possible when this drug is used in first-line therapy?. Viruses, 2014; 6:3377–3385.
64.
GillVC, LynchT, RamazaniS, KrentzHB: Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: A word of caution. Antivir Ther, 2017; 22:277–286.
65.
BuchaczK, YoungB, PalellaFJ Jr., ArmonC, BrooksJT: Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999–2011. J Antimicrob Chemother, 2015; 70:2337–2346.
66.
DasguptaS, HallHI, HernandezAL, OcfemiaMCB, SaduvalaN, OsterAM: Receipt and timing of HIV drug resistance testing in six U.S. jurisdictions. AIDS Care, 2017; 29:1567–1575.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
